APA (7th ed.) Citation

Wring, S., Murphy, G., Atiee, G., Corr, C., Hyman, M., Willett, M., & Angulo, D. (2018). Lack of Impact by SCY‐078, a First‐in‐Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug‐Drug Interactions. Journal of Clinical Pharmacology, 58(10), 1305. https://doi.org/10.1002/jcph.1146

Chicago Style (17th ed.) Citation

Wring, Stephen, Gail Murphy, George Atiee, Christy Corr, Michele Hyman, Michael Willett, and David Angulo. "Lack of Impact by SCY‐078, a First‐in‐Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug‐Drug Interactions." Journal of Clinical Pharmacology 58, no. 10 (2018): 1305. https://doi.org/10.1002/jcph.1146.

MLA (9th ed.) Citation

Wring, Stephen, et al. "Lack of Impact by SCY‐078, a First‐in‐Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug‐Drug Interactions." Journal of Clinical Pharmacology, vol. 58, no. 10, 2018, p. 1305, https://doi.org/10.1002/jcph.1146.